AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Repertoire Immune Medicines has signed a partnership and licence agreement with Genentech, focusing on T cell-targeted immune ...

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing ...

EditCo Bio has entered a licensing agreement to secure access to Promega’s protein-tagging and bioluminescent identification ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

ConcertAI has announced an agreement with Bayer that allows the latter to utilise its Translational360 and AI SaaS solutions.

The public cash offer, via a newly formed company by KKR called RWK BidCo, is for Skr145 per share in Biotage. The offer, ...

In April 2025, the EU announced details about the first two medicinal products to undergo joint clinical assessments (JCAs).